| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 187 | 2024 | 6982 | 6.860 |
Why?
|
| Transplantation Conditioning | 94 | 2022 | 2359 | 4.410 |
Why?
|
| Graft vs Host Disease | 84 | 2024 | 2804 | 3.920 |
Why?
|
| Multiple Myeloma | 48 | 2023 | 2321 | 2.950 |
Why?
|
| Stem Cell Transplantation | 32 | 2023 | 1424 | 2.710 |
Why?
|
| Cord Blood Stem Cell Transplantation | 18 | 2021 | 372 | 2.540 |
Why?
|
| Transplantation, Autologous | 69 | 2023 | 2049 | 2.490 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 12 | 2022 | 271 | 2.330 |
Why?
|
| Melphalan | 44 | 2023 | 877 | 2.040 |
Why?
|
| Lymphoma, Non-Hodgkin | 16 | 2023 | 1068 | 1.800 |
Why?
|
| Busulfan | 30 | 2023 | 786 | 1.710 |
Why?
|
| Transplantation, Homologous | 72 | 2024 | 3033 | 1.660 |
Why?
|
| Hematologic Neoplasms | 34 | 2024 | 1955 | 1.610 |
Why?
|
| Hodgkin Disease | 20 | 2023 | 1486 | 1.480 |
Why?
|
| Myeloablative Agonists | 21 | 2022 | 386 | 1.470 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 10 | 2018 | 218 | 1.380 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 62 | 2024 | 16593 | 1.290 |
Why?
|
| Leukemia, Myeloid, Acute | 34 | 2023 | 7240 | 1.290 |
Why?
|
| Cyclophosphamide | 25 | 2024 | 3231 | 1.260 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 10 | 2022 | 770 | 1.260 |
Why?
|
| Lymphoma | 11 | 2019 | 1514 | 1.240 |
Why?
|
| Vidarabine | 32 | 2022 | 1383 | 1.230 |
Why?
|
| Middle Aged | 215 | 2024 | 90020 | 1.200 |
Why?
|
| Myelodysplastic Syndromes | 21 | 2023 | 3145 | 1.190 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 17 | 2023 | 1734 | 1.160 |
Why?
|
| Adult | 200 | 2024 | 81555 | 1.150 |
Why?
|
| Tacrolimus | 16 | 2023 | 351 | 1.110 |
Why?
|
| Leukapheresis | 6 | 2014 | 166 | 1.100 |
Why?
|
| Aged | 175 | 2024 | 73160 | 1.070 |
Why?
|
| T-Lymphocytes | 12 | 2020 | 3928 | 1.020 |
Why?
|
| Hematopoietic Stem Cells | 8 | 2017 | 1372 | 1.020 |
Why?
|
| Recurrence | 45 | 2023 | 4881 | 0.990 |
Why?
|
| Neoplasms, Second Primary | 8 | 2023 | 1379 | 0.980 |
Why?
|
| Fetal Blood | 12 | 2023 | 503 | 0.940 |
Why?
|
| Humans | 294 | 2024 | 270946 | 0.920 |
Why?
|
| Male | 205 | 2024 | 128453 | 0.910 |
Why?
|
| Immunosuppressive Agents | 17 | 2021 | 1445 | 0.850 |
Why?
|
| Young Adult | 76 | 2024 | 22059 | 0.840 |
Why?
|
| Heterocyclic Compounds | 5 | 2022 | 119 | 0.840 |
Why?
|
| Female | 202 | 2024 | 148508 | 0.840 |
Why?
|
| Treatment Outcome | 100 | 2024 | 33827 | 0.820 |
Why?
|
| Blood Banks | 1 | 2021 | 29 | 0.780 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 10 | 2020 | 2474 | 0.760 |
Why?
|
| Graft Survival | 15 | 2017 | 1091 | 0.730 |
Why?
|
| Disease-Free Survival | 54 | 2019 | 10250 | 0.730 |
Why?
|
| Adolescent | 81 | 2024 | 32577 | 0.720 |
Why?
|
| Salvage Therapy | 17 | 2018 | 2117 | 0.710 |
Why?
|
| Allografts | 20 | 2024 | 684 | 0.710 |
Why?
|
| Survival Analysis | 41 | 2022 | 9307 | 0.680 |
Why?
|
| Retrospective Studies | 88 | 2024 | 39694 | 0.680 |
Why?
|
| Antigens, CD19 | 7 | 2024 | 584 | 0.670 |
Why?
|
| Transplantation, Haploidentical | 6 | 2024 | 159 | 0.640 |
Why?
|
| Lymphoma, B-Cell | 4 | 2023 | 935 | 0.630 |
Why?
|
| Remission Induction | 30 | 2022 | 3645 | 0.630 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 12 | 2022 | 2899 | 0.630 |
Why?
|
| Unrelated Donors | 8 | 2020 | 321 | 0.620 |
Why?
|
| Lymphoma, T-Cell | 4 | 2016 | 369 | 0.620 |
Why?
|
| Rituximab | 19 | 2023 | 1589 | 0.590 |
Why?
|
| Nucleic Acids | 1 | 2017 | 43 | 0.570 |
Why?
|
| Chimerism | 1 | 2017 | 65 | 0.560 |
Why?
|
| Blood Donors | 4 | 2014 | 173 | 0.560 |
Why?
|
| Etoposide | 8 | 2024 | 905 | 0.560 |
Why?
|
| Antigens, CD34 | 8 | 2022 | 642 | 0.560 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 4 | 2024 | 191 | 0.540 |
Why?
|
| Scleroderma, Systemic | 4 | 2018 | 160 | 0.540 |
Why?
|
| Antibodies, Monoclonal | 17 | 2014 | 4510 | 0.540 |
Why?
|
| Whole-Body Irradiation | 7 | 2017 | 324 | 0.540 |
Why?
|
| Acute Kidney Injury | 3 | 2014 | 779 | 0.540 |
Why?
|
| HIV | 1 | 2017 | 237 | 0.520 |
Why?
|
| Adenine Nucleotides | 7 | 2016 | 365 | 0.520 |
Why?
|
| Killer Cells, Natural | 8 | 2024 | 958 | 0.500 |
Why?
|
| Drug Resistance, Multiple, Viral | 1 | 2014 | 8 | 0.500 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 2 | 2015 | 303 | 0.490 |
Why?
|
| Arabinonucleosides | 7 | 2016 | 458 | 0.490 |
Why?
|
| Survival Rate | 40 | 2019 | 12516 | 0.480 |
Why?
|
| Organophosphonates | 1 | 2014 | 63 | 0.470 |
Why?
|
| Photopheresis | 5 | 2021 | 79 | 0.460 |
Why?
|
| Herpes Simplex | 1 | 2014 | 102 | 0.460 |
Why?
|
| Cytosine | 1 | 2014 | 156 | 0.450 |
Why?
|
| Prognosis | 43 | 2024 | 22458 | 0.450 |
Why?
|
| Antiviral Agents | 5 | 2014 | 1255 | 0.450 |
Why?
|
| Blood Volume | 1 | 2013 | 106 | 0.440 |
Why?
|
| Immunotherapy, Adoptive | 7 | 2024 | 1838 | 0.440 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 7 | 2017 | 2633 | 0.430 |
Why?
|
| Histocompatibility Testing | 10 | 2018 | 483 | 0.430 |
Why?
|
| Sezary Syndrome | 2 | 2014 | 167 | 0.420 |
Why?
|
| Antineoplastic Agents | 20 | 2020 | 14679 | 0.420 |
Why?
|
| Neoplasm Recurrence, Local | 19 | 2023 | 10349 | 0.420 |
Why?
|
| Follow-Up Studies | 34 | 2019 | 15253 | 0.400 |
Why?
|
| Bronchiolitis Obliterans | 2 | 2023 | 94 | 0.400 |
Why?
|
| Bone Marrow Transplantation | 10 | 2024 | 1773 | 0.400 |
Why?
|
| Combined Modality Therapy | 25 | 2020 | 9043 | 0.390 |
Why?
|
| Receptors, Antigen, T-Cell | 5 | 2022 | 1135 | 0.380 |
Why?
|
| Cell- and Tissue-Based Therapy | 4 | 2020 | 381 | 0.380 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 13 | 2014 | 880 | 0.370 |
Why?
|
| Hepatic Veno-Occlusive Disease | 2 | 2024 | 135 | 0.370 |
Why?
|
| Lymphoma, Follicular | 5 | 2016 | 636 | 0.370 |
Why?
|
| Scleroderma, Localized | 1 | 2010 | 13 | 0.370 |
Why?
|
| Incidence | 19 | 2024 | 5843 | 0.370 |
Why?
|
| Immunocompromised Host | 2 | 2014 | 721 | 0.360 |
Why?
|
| Tissue Donors | 5 | 2022 | 812 | 0.350 |
Why?
|
| Risk Factors | 29 | 2024 | 17823 | 0.350 |
Why?
|
| Amyloidosis | 3 | 2016 | 185 | 0.340 |
Why?
|
| Ki-1 Antigen | 2 | 2024 | 185 | 0.330 |
Why?
|
| Antineoplastic Agents, Alkylating | 6 | 2018 | 609 | 0.330 |
Why?
|
| Lymphocyte Transfusion | 4 | 2017 | 174 | 0.320 |
Why?
|
| Depsipeptides | 4 | 2016 | 78 | 0.320 |
Why?
|
| Prednisone | 2 | 2024 | 1039 | 0.320 |
Why?
|
| Body Weight | 1 | 2013 | 1333 | 0.320 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2010 | 262 | 0.320 |
Why?
|
| Sirolimus | 3 | 2021 | 831 | 0.310 |
Why?
|
| Respiratory Syncytial Virus Infections | 4 | 2014 | 435 | 0.310 |
Why?
|
| Thrombotic Microangiopathies | 2 | 2019 | 62 | 0.310 |
Why?
|
| Neoplasms | 11 | 2024 | 15849 | 0.300 |
Why?
|
| Acute Disease | 13 | 2024 | 2515 | 0.300 |
Why?
|
| Antilymphocyte Serum | 6 | 2020 | 237 | 0.300 |
Why?
|
| Deoxycytidine | 8 | 2018 | 1377 | 0.300 |
Why?
|
| Kaplan-Meier Estimate | 17 | 2019 | 6248 | 0.300 |
Why?
|
| Bone Marrow | 8 | 2021 | 2434 | 0.300 |
Why?
|
| Age Factors | 9 | 2020 | 5496 | 0.290 |
Why?
|
| Child | 31 | 2023 | 30418 | 0.290 |
Why?
|
| Filgrastim | 5 | 2013 | 194 | 0.280 |
Why?
|
| Prospective Studies | 19 | 2024 | 13351 | 0.280 |
Why?
|
| Virus Activation | 3 | 2018 | 236 | 0.280 |
Why?
|
| Mycosis Fungoides | 1 | 2010 | 335 | 0.280 |
Why?
|
| Histocompatibility | 4 | 2018 | 182 | 0.280 |
Why?
|
| Ribavirin | 4 | 2022 | 177 | 0.270 |
Why?
|
| Primary Myelofibrosis | 3 | 2023 | 902 | 0.270 |
Why?
|
| Neutrophils | 5 | 2017 | 870 | 0.270 |
Why?
|
| Hydroxamic Acids | 4 | 2016 | 459 | 0.270 |
Why?
|
| Respiratory Tract Infections | 3 | 2017 | 409 | 0.270 |
Why?
|
| Cytarabine | 6 | 2019 | 2014 | 0.260 |
Why?
|
| Mycophenolic Acid | 4 | 2022 | 156 | 0.260 |
Why?
|
| Skin Neoplasms | 3 | 2021 | 4840 | 0.260 |
Why?
|
| Neoplasm, Residual | 5 | 2022 | 1740 | 0.260 |
Why?
|
| Benzoates | 2 | 2024 | 130 | 0.260 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2021 | 1021 | 0.250 |
Why?
|
| Immunoglobulin Light Chains | 2 | 2016 | 112 | 0.250 |
Why?
|
| Chromosomes, Human, Pair 14 | 2 | 2019 | 287 | 0.250 |
Why?
|
| Leukemia | 4 | 2023 | 1720 | 0.250 |
Why?
|
| Receptors, Antigen | 2 | 2017 | 68 | 0.250 |
Why?
|
| Aged, 80 and over | 23 | 2023 | 30940 | 0.250 |
Why?
|
| ABO Blood-Group System | 3 | 2016 | 132 | 0.250 |
Why?
|
| Stem Cells | 2 | 2015 | 1230 | 0.240 |
Why?
|
| Chromosomes, Human, Pair 11 | 2 | 2019 | 410 | 0.240 |
Why?
|
| Hydrazines | 2 | 2024 | 214 | 0.240 |
Why?
|
| HIV Infections | 1 | 2017 | 2163 | 0.240 |
Why?
|
| Pentostatin | 2 | 2017 | 121 | 0.240 |
Why?
|
| Red-Cell Aplasia, Pure | 2 | 2016 | 50 | 0.240 |
Why?
|
| Dose-Response Relationship, Drug | 9 | 2018 | 5108 | 0.240 |
Why?
|
| Carmustine | 4 | 2019 | 224 | 0.240 |
Why?
|
| Piperazines | 2 | 2010 | 2153 | 0.230 |
Why?
|
| Lymphocyte Depletion | 2 | 2018 | 311 | 0.230 |
Why?
|
| Pyrimidines | 3 | 2015 | 3667 | 0.230 |
Why?
|
| Paramyxoviridae Infections | 2 | 2017 | 72 | 0.230 |
Why?
|
| Leukocyte Transfusion | 3 | 2014 | 44 | 0.230 |
Why?
|
| Doxorubicin | 4 | 2024 | 3138 | 0.230 |
Why?
|
| Transplantation Chimera | 6 | 2014 | 173 | 0.230 |
Why?
|
| HLA Antigens | 3 | 2016 | 575 | 0.230 |
Why?
|
| Drug Therapy, Combination | 9 | 2022 | 2368 | 0.230 |
Why?
|
| Toxoplasmosis | 1 | 2024 | 49 | 0.230 |
Why?
|
| Thalidomide | 5 | 2017 | 600 | 0.220 |
Why?
|
| Immunologic Factors | 4 | 2016 | 670 | 0.220 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 2 | 2017 | 204 | 0.220 |
Why?
|
| Retreatment | 4 | 2018 | 451 | 0.220 |
Why?
|
| Pyrazoles | 3 | 2024 | 1542 | 0.220 |
Why?
|
| Hepatitis E virus | 1 | 2022 | 11 | 0.210 |
Why?
|
| Time Factors | 16 | 2020 | 13112 | 0.210 |
Why?
|
| Hepatitis E | 1 | 2022 | 13 | 0.210 |
Why?
|
| Ifosfamide | 4 | 2018 | 357 | 0.210 |
Why?
|
| Immunologic Deficiency Syndromes | 2 | 2015 | 255 | 0.210 |
Why?
|
| Cytomegalovirus Infections | 3 | 2020 | 486 | 0.210 |
Why?
|
| Autografts | 3 | 2018 | 179 | 0.210 |
Why?
|
| Aerosols | 2 | 2013 | 149 | 0.210 |
Why?
|
| Leukemia, Myeloid | 3 | 2007 | 994 | 0.200 |
Why?
|
| Encephalitis | 1 | 2003 | 155 | 0.200 |
Why?
|
| Dendritic Cells | 3 | 2021 | 1108 | 0.200 |
Why?
|
| West Nile virus | 1 | 2003 | 132 | 0.200 |
Why?
|
| Myeloproliferative Disorders | 2 | 2021 | 881 | 0.200 |
Why?
|
| Chromosome Aberrations | 5 | 2020 | 2023 | 0.190 |
Why?
|
| Vascular Diseases | 1 | 2024 | 243 | 0.190 |
Why?
|
| West Nile Fever | 1 | 2003 | 155 | 0.190 |
Why?
|
| Drug Administration Schedule | 9 | 2019 | 3542 | 0.190 |
Why?
|
| Vascularized Composite Allotransplantation | 1 | 2021 | 29 | 0.190 |
Why?
|
| Recombinant Proteins | 5 | 2013 | 3075 | 0.190 |
Why?
|
| B-Lymphocytes | 5 | 2022 | 1424 | 0.190 |
Why?
|
| Thrombocytopenia | 3 | 2021 | 872 | 0.190 |
Why?
|
| Transplant Recipients | 2 | 2020 | 337 | 0.190 |
Why?
|
| Hemorrhagic Disorders | 1 | 2021 | 52 | 0.190 |
Why?
|
| Translocation, Genetic | 2 | 2019 | 1287 | 0.190 |
Why?
|
| Methotrexate | 5 | 2023 | 1027 | 0.180 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2021 | 88 | 0.180 |
Why?
|
| Benzylamines | 4 | 2013 | 101 | 0.180 |
Why?
|
| Disease Progression | 12 | 2018 | 6893 | 0.180 |
Why?
|
| Feasibility Studies | 7 | 2020 | 2346 | 0.180 |
Why?
|
| Cryopreservation | 1 | 2021 | 171 | 0.180 |
Why?
|
| Blood Platelets | 3 | 2015 | 682 | 0.180 |
Why?
|
| Cystitis | 1 | 2021 | 109 | 0.180 |
Why?
|
| Kidney Diseases | 2 | 2016 | 726 | 0.180 |
Why?
|
| Antigens, Neoplasm | 2 | 2020 | 1589 | 0.180 |
Why?
|
| Vaginal Neoplasms | 1 | 2001 | 155 | 0.170 |
Why?
|
| Gastrointestinal Diseases | 3 | 2024 | 619 | 0.170 |
Why?
|
| Complement Inactivating Agents | 1 | 2019 | 17 | 0.170 |
Why?
|
| Mortality | 3 | 2018 | 353 | 0.170 |
Why?
|
| Skin Ulcer | 1 | 2020 | 74 | 0.170 |
Why?
|
| Bortezomib | 3 | 2018 | 553 | 0.170 |
Why?
|
| Child, Preschool | 16 | 2017 | 16978 | 0.170 |
Why?
|
| Tumor Burden | 1 | 2005 | 2034 | 0.170 |
Why?
|
| Cause of Death | 3 | 2017 | 784 | 0.160 |
Why?
|
| Lymphoma, Mantle-Cell | 3 | 2014 | 746 | 0.160 |
Why?
|
| Intestinal Neoplasms | 1 | 2001 | 201 | 0.160 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2019 | 3397 | 0.160 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily C | 1 | 2018 | 22 | 0.160 |
Why?
|
| POEMS Syndrome | 1 | 2018 | 23 | 0.160 |
Why?
|
| Epigenesis, Genetic | 2 | 2016 | 1432 | 0.160 |
Why?
|
| Immunotherapy | 3 | 2018 | 3532 | 0.160 |
Why?
|
| Dexamethasone | 3 | 2014 | 1506 | 0.160 |
Why?
|
| Lung Transplantation | 1 | 2023 | 389 | 0.160 |
Why?
|
| Graft vs Tumor Effect | 5 | 2012 | 143 | 0.160 |
Why?
|
| Immunoglobulin Light-chain Amyloidosis | 1 | 2018 | 33 | 0.160 |
Why?
|
| Graft Enhancement, Immunologic | 2 | 2015 | 38 | 0.160 |
Why?
|
| Thymus Neoplasms | 1 | 2023 | 420 | 0.150 |
Why?
|
| Psoriasis | 1 | 2019 | 138 | 0.150 |
Why?
|
| HLA-DRB1 Chains | 1 | 2018 | 81 | 0.150 |
Why?
|
| Cytomegalovirus | 2 | 2018 | 493 | 0.150 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2001 | 331 | 0.150 |
Why?
|
| Induction Chemotherapy | 2 | 2018 | 671 | 0.150 |
Why?
|
| Polyethylene Glycols | 3 | 2013 | 641 | 0.150 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2017 | 1836 | 0.150 |
Why?
|
| Multivariate Analysis | 9 | 2017 | 4331 | 0.150 |
Why?
|
| Adoptive Transfer | 3 | 2017 | 435 | 0.150 |
Why?
|
| Gestational Age | 1 | 2021 | 1143 | 0.150 |
Why?
|
| Plateletpheresis | 1 | 2017 | 11 | 0.150 |
Why?
|
| Anemia, Hemolytic | 2 | 2008 | 54 | 0.150 |
Why?
|
| Receptor-CD3 Complex, Antigen, T-Cell | 1 | 2017 | 8 | 0.140 |
Why?
|
| Leukemia, Prolymphocytic, T-Cell | 1 | 2017 | 48 | 0.140 |
Why?
|
| Family | 1 | 2021 | 762 | 0.140 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2017 | 128 | 0.140 |
Why?
|
| Immunoblastic Lymphadenopathy | 1 | 2016 | 30 | 0.140 |
Why?
|
| Hepatitis B Antibodies | 1 | 2017 | 56 | 0.140 |
Why?
|
| Methylprednisolone | 2 | 2009 | 200 | 0.140 |
Why?
|
| Clinical Trials as Topic | 4 | 2019 | 3862 | 0.140 |
Why?
|
| Postoperative Care | 1 | 2020 | 729 | 0.140 |
Why?
|
| Epidemiologic Methods | 1 | 2017 | 252 | 0.140 |
Why?
|
| Body Fluids | 1 | 2017 | 124 | 0.140 |
Why?
|
| B-Lymphocytes, Regulatory | 1 | 2016 | 23 | 0.140 |
Why?
|
| Chromosome Deletion | 2 | 2014 | 1056 | 0.140 |
Why?
|
| Blood Cell Count | 2 | 2013 | 234 | 0.140 |
Why?
|
| Vincristine | 2 | 2018 | 1572 | 0.130 |
Why?
|
| CDC2-CDC28 Kinases | 1 | 2016 | 132 | 0.130 |
Why?
|
| Receptors, KIR | 1 | 2016 | 63 | 0.130 |
Why?
|
| Natural Killer T-Cells | 1 | 2017 | 121 | 0.130 |
Why?
|
| CD28 Antigens | 1 | 2017 | 204 | 0.130 |
Why?
|
| Thrombocytosis | 1 | 2017 | 141 | 0.130 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2021 | 550 | 0.130 |
Why?
|
| Heart Diseases | 2 | 2014 | 738 | 0.130 |
Why?
|
| Immunoglobulin lambda-Chains | 1 | 2015 | 45 | 0.130 |
Why?
|
| Edema | 1 | 2017 | 263 | 0.130 |
Why?
|
| Graft vs Leukemia Effect | 2 | 2013 | 107 | 0.130 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2020 | 475 | 0.130 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2019 | 286 | 0.130 |
Why?
|
| Plasmablastic Lymphoma | 1 | 2015 | 38 | 0.130 |
Why?
|
| Pancytopenia | 1 | 2016 | 119 | 0.130 |
Why?
|
| Neoplasm Staging | 8 | 2019 | 13976 | 0.130 |
Why?
|
| Oxides | 3 | 2014 | 212 | 0.130 |
Why?
|
| Aftercare | 1 | 2017 | 254 | 0.130 |
Why?
|
| Proportional Hazards Models | 7 | 2023 | 5085 | 0.130 |
Why?
|
| Arsenicals | 3 | 2014 | 204 | 0.130 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2015 | 135 | 0.120 |
Why?
|
| Fucose | 1 | 2015 | 60 | 0.120 |
Why?
|
| DNA Transposable Elements | 1 | 2016 | 252 | 0.120 |
Why?
|
| Immunoconjugates | 2 | 2016 | 315 | 0.120 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2018 | 3657 | 0.120 |
Why?
|
| Gastrointestinal Tract | 1 | 2017 | 326 | 0.120 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2017 | 5411 | 0.120 |
Why?
|
| Cytokines | 4 | 2023 | 2836 | 0.120 |
Why?
|
| Lymphocyte Activation | 2 | 2016 | 1733 | 0.120 |
Why?
|
| Community-Acquired Infections | 1 | 2017 | 286 | 0.120 |
Why?
|
| Ring Chromosomes | 1 | 2014 | 17 | 0.120 |
Why?
|
| Leukocytosis | 1 | 2014 | 115 | 0.120 |
Why?
|
| Administration, Topical | 1 | 2014 | 264 | 0.120 |
Why?
|
| Outpatients | 1 | 2017 | 470 | 0.120 |
Why?
|
| Chronic Disease | 8 | 2022 | 1851 | 0.120 |
Why?
|
| Weight Gain | 1 | 2017 | 475 | 0.120 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2017 | 1666 | 0.120 |
Why?
|
| Blood Preservation | 1 | 2014 | 60 | 0.110 |
Why?
|
| Blood | 1 | 2014 | 171 | 0.110 |
Why?
|
| Granulocyte Precursor Cells | 1 | 2013 | 36 | 0.110 |
Why?
|
| Leukocyte Count | 3 | 2014 | 738 | 0.110 |
Why?
|
| Positron-Emission Tomography | 4 | 2015 | 2198 | 0.110 |
Why?
|
| Indoles | 2 | 2016 | 1035 | 0.110 |
Why?
|
| Interleukin-10 | 1 | 2016 | 481 | 0.110 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2022 | 1050 | 0.110 |
Why?
|
| Gene Amplification | 1 | 2016 | 769 | 0.110 |
Why?
|
| Gastric Antral Vascular Ectasia | 1 | 2013 | 3 | 0.110 |
Why?
|
| Central Venous Catheters | 1 | 2014 | 100 | 0.110 |
Why?
|
| Mutant Chimeric Proteins | 1 | 2013 | 25 | 0.110 |
Why?
|
| Scleroderma, Diffuse | 1 | 2013 | 6 | 0.110 |
Why?
|
| Meningeal Neoplasms | 1 | 2018 | 473 | 0.110 |
Why?
|
| Granulocytes | 1 | 2014 | 243 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2014 | 228 | 0.110 |
Why?
|
| Cell Culture Techniques | 3 | 2014 | 580 | 0.110 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 319 | 0.110 |
Why?
|
| Immune Tolerance | 2 | 2013 | 425 | 0.110 |
Why?
|
| Tissue Engineering | 1 | 2015 | 253 | 0.110 |
Why?
|
| Virus Diseases | 2 | 2015 | 392 | 0.110 |
Why?
|
| Gene Deletion | 2 | 2016 | 1482 | 0.110 |
Why?
|
| Propensity Score | 3 | 2021 | 774 | 0.110 |
Why?
|
| Cell Survival | 2 | 2016 | 3081 | 0.100 |
Why?
|
| Cohort Studies | 9 | 2017 | 9433 | 0.100 |
Why?
|
| Adenoviridae Infections | 1 | 2013 | 114 | 0.100 |
Why?
|
| Cell Count | 1 | 2013 | 524 | 0.100 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2016 | 627 | 0.100 |
Why?
|
| Inpatients | 1 | 2017 | 691 | 0.100 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2013 | 426 | 0.100 |
Why?
|
| Ascorbic Acid | 2 | 2011 | 130 | 0.100 |
Why?
|
| Plasma Exchange | 2 | 2010 | 103 | 0.100 |
Why?
|
| Steroids | 4 | 2021 | 376 | 0.100 |
Why?
|
| Autoimmune Diseases | 1 | 2005 | 425 | 0.100 |
Why?
|
| Severity of Illness Index | 4 | 2017 | 4399 | 0.100 |
Why?
|
| Blood Transfusion, Autologous | 1 | 2011 | 75 | 0.100 |
Why?
|
| Drug Synergism | 4 | 2016 | 1369 | 0.100 |
Why?
|
| Adenosine Deaminase Inhibitors | 1 | 2010 | 24 | 0.090 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2014 | 439 | 0.090 |
Why?
|
| Catheter-Related Infections | 1 | 2014 | 276 | 0.090 |
Why?
|
| Gallium Radioisotopes | 2 | 2008 | 62 | 0.090 |
Why?
|
| Adenoviridae | 2 | 2013 | 1510 | 0.090 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 1 | 2010 | 46 | 0.090 |
Why?
|
| Hepacivirus | 2 | 2016 | 421 | 0.090 |
Why?
|
| Cardiomyopathies | 1 | 2016 | 559 | 0.090 |
Why?
|
| Hepatitis C | 1 | 2016 | 549 | 0.090 |
Why?
|
| Cross Infection | 2 | 2017 | 548 | 0.090 |
Why?
|
| Genotype | 2 | 2016 | 4109 | 0.090 |
Why?
|
| Vitamin D Deficiency | 1 | 2011 | 121 | 0.090 |
Why?
|
| Patient Selection | 1 | 2017 | 2042 | 0.090 |
Why?
|
| United States | 7 | 2022 | 15982 | 0.090 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2010 | 382 | 0.090 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2012 | 215 | 0.090 |
Why?
|
| Exercise | 1 | 2017 | 1211 | 0.090 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2014 | 2471 | 0.090 |
Why?
|
| Genes, MHC Class I | 1 | 2009 | 48 | 0.090 |
Why?
|
| Boronic Acids | 1 | 2011 | 366 | 0.080 |
Why?
|
| Interleukin-2 | 2 | 2010 | 891 | 0.080 |
Why?
|
| Vitamin D | 1 | 2011 | 261 | 0.080 |
Why?
|
| Osteoporosis | 1 | 2011 | 237 | 0.080 |
Why?
|
| Glomerular Filtration Rate | 2 | 2009 | 600 | 0.080 |
Why?
|
| Central Nervous System | 2 | 2022 | 459 | 0.080 |
Why?
|
| Alleles | 1 | 2015 | 2508 | 0.080 |
Why?
|
| Consolidation Chemotherapy | 2 | 2024 | 154 | 0.080 |
Why?
|
| Imatinib Mesylate | 2 | 2010 | 1691 | 0.080 |
Why?
|
| Injections, Subcutaneous | 2 | 2006 | 345 | 0.080 |
Why?
|
| Pneumonia, Viral | 1 | 2017 | 707 | 0.080 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2020 | 2314 | 0.080 |
Why?
|
| Influenza, Human | 1 | 2015 | 759 | 0.080 |
Why?
|
| Pyrazines | 1 | 2011 | 524 | 0.080 |
Why?
|
| Radiotherapy | 1 | 2015 | 1858 | 0.080 |
Why?
|
| Ethylenediamines | 1 | 2008 | 22 | 0.080 |
Why?
|
| Models, Biological | 1 | 2017 | 3226 | 0.080 |
Why?
|
| Blood Group Incompatibility | 1 | 2008 | 39 | 0.080 |
Why?
|
| Fatal Outcome | 3 | 2006 | 839 | 0.080 |
Why?
|
| Infection Control | 1 | 2010 | 276 | 0.080 |
Why?
|
| Case-Control Studies | 5 | 2017 | 6027 | 0.070 |
Why?
|
| Maintenance Chemotherapy | 2 | 2019 | 224 | 0.070 |
Why?
|
| Chi-Square Distribution | 2 | 2017 | 1323 | 0.070 |
Why?
|
| Cytogenetic Analysis | 2 | 2020 | 574 | 0.070 |
Why?
|
| Benzamides | 2 | 2010 | 1883 | 0.070 |
Why?
|
| Infusions, Intravenous | 4 | 2012 | 1438 | 0.070 |
Why?
|
| Chelating Agents | 1 | 2008 | 130 | 0.070 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2018 | 2168 | 0.070 |
Why?
|
| Hepatitis B | 1 | 2010 | 272 | 0.070 |
Why?
|
| Predictive Value of Tests | 4 | 2018 | 4983 | 0.070 |
Why?
|
| Copper | 1 | 2008 | 166 | 0.070 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2013 | 1088 | 0.070 |
Why?
|
| Bayes Theorem | 2 | 2022 | 1036 | 0.070 |
Why?
|
| Aminoglycosides | 1 | 2007 | 235 | 0.070 |
Why?
|
| Stroke Volume | 1 | 2009 | 578 | 0.070 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2024 | 1467 | 0.070 |
Why?
|
| Treatment Failure | 3 | 2017 | 1433 | 0.070 |
Why?
|
| Renal Insufficiency | 1 | 2009 | 317 | 0.070 |
Why?
|
| Strongyloidiasis | 1 | 2006 | 58 | 0.070 |
Why?
|
| Biopsy | 3 | 2020 | 3545 | 0.070 |
Why?
|
| Signal Transduction | 4 | 2017 | 12206 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2007 | 347 | 0.070 |
Why?
|
| Regression Analysis | 1 | 2009 | 1567 | 0.070 |
Why?
|
| Antigens, CD20 | 1 | 2006 | 210 | 0.070 |
Why?
|
| Postoperative Complications | 1 | 2021 | 5685 | 0.060 |
Why?
|
| Recovery of Function | 1 | 2009 | 690 | 0.060 |
Why?
|
| Texas | 5 | 2017 | 6415 | 0.060 |
Why?
|
| Flow Cytometry | 3 | 2018 | 3083 | 0.060 |
Why?
|
| Antioxidants | 1 | 2008 | 521 | 0.060 |
Why?
|
| Proteasome Inhibitors | 2 | 2017 | 238 | 0.060 |
Why?
|
| Radiopharmaceuticals | 2 | 2008 | 1338 | 0.060 |
Why?
|
| RNA, Messenger | 2 | 2016 | 6483 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2020 | 4956 | 0.060 |
Why?
|
| Intention to Treat Analysis | 2 | 2018 | 125 | 0.060 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2008 | 1260 | 0.060 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2010 | 1144 | 0.060 |
Why?
|
| Comorbidity | 2 | 2023 | 2430 | 0.060 |
Why?
|
| Minnesota | 1 | 2024 | 126 | 0.060 |
Why?
|
| Liver Failure, Acute | 1 | 2005 | 98 | 0.060 |
Why?
|
| Blood Pressure | 1 | 2010 | 1594 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 3655 | 0.060 |
Why?
|
| Chromatin Assembly and Disassembly | 2 | 2016 | 294 | 0.060 |
Why?
|
| Renal Dialysis | 1 | 2010 | 921 | 0.050 |
Why?
|
| Haplotypes | 2 | 2018 | 848 | 0.050 |
Why?
|
| Kinetics | 1 | 2006 | 2247 | 0.050 |
Why?
|
| Polymyositis | 1 | 2002 | 10 | 0.050 |
Why?
|
| Time | 1 | 2003 | 185 | 0.050 |
Why?
|
| Interleukin-15 | 1 | 2024 | 189 | 0.050 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2024 | 212 | 0.050 |
Why?
|
| Immunophenotyping | 2 | 2017 | 1730 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2010 | 2670 | 0.050 |
Why?
|
| Azacitidine | 2 | 2020 | 1215 | 0.050 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2004 | 266 | 0.050 |
Why?
|
| Donor Selection | 1 | 2022 | 106 | 0.050 |
Why?
|
| Administration, Inhalation | 2 | 2013 | 299 | 0.050 |
Why?
|
| Viremia | 1 | 2022 | 181 | 0.050 |
Why?
|
| Drug Resistance | 2 | 2018 | 615 | 0.050 |
Why?
|
| Glucocorticoids | 1 | 2005 | 628 | 0.050 |
Why?
|
| Kidney | 1 | 2010 | 2261 | 0.050 |
Why?
|
| Biomarkers | 3 | 2018 | 5106 | 0.050 |
Why?
|
| Risk Assessment | 4 | 2018 | 6837 | 0.050 |
Why?
|
| Ferritins | 1 | 2021 | 154 | 0.050 |
Why?
|
| Statistics, Nonparametric | 1 | 2003 | 989 | 0.050 |
Why?
|
| Brain Neoplasms | 1 | 2018 | 4983 | 0.050 |
Why?
|
| Siblings | 1 | 2022 | 299 | 0.040 |
Why?
|
| Spirometry | 1 | 2020 | 147 | 0.040 |
Why?
|
| Germinal Center | 1 | 2021 | 168 | 0.040 |
Why?
|
| Azithromycin | 1 | 2020 | 79 | 0.040 |
Why?
|
| Receptors, Cytokine | 1 | 2021 | 183 | 0.040 |
Why?
|
| Brain Diseases | 1 | 2003 | 417 | 0.040 |
Why?
|
| Podophyllotoxin | 1 | 2019 | 65 | 0.040 |
Why?
|
| Invasive Fungal Infections | 1 | 2020 | 54 | 0.040 |
Why?
|
| Infant | 4 | 2017 | 13913 | 0.040 |
Why?
|
| Cell Line, Tumor | 4 | 2016 | 14864 | 0.040 |
Why?
|
| Mothers | 1 | 2022 | 418 | 0.040 |
Why?
|
| Butyrophenones | 1 | 2019 | 13 | 0.040 |
Why?
|
| Retroviridae | 1 | 2020 | 376 | 0.040 |
Why?
|
| Ascites | 1 | 2020 | 216 | 0.040 |
Why?
|
| Plasmapheresis | 1 | 2018 | 52 | 0.040 |
Why?
|
| Chromosomes | 1 | 2019 | 323 | 0.040 |
Why?
|
| Immunologic Surveillance | 1 | 2018 | 61 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 2 | 2016 | 5834 | 0.040 |
Why?
|
| Biomarkers, Tumor | 4 | 2020 | 10698 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 1617 | 0.040 |
Why?
|
| Injections, Intralesional | 1 | 2018 | 166 | 0.040 |
Why?
|
| Bisoprolol | 1 | 2017 | 13 | 0.040 |
Why?
|
| Adrenergic beta-2 Receptor Antagonists | 1 | 2017 | 18 | 0.040 |
Why?
|
| DNA Damage | 2 | 2016 | 1980 | 0.040 |
Why?
|
| Peripheral Blood Stem Cells | 1 | 2017 | 9 | 0.040 |
Why?
|
| Plasma Cells | 1 | 2018 | 202 | 0.040 |
Why?
|
| Nadolol | 1 | 2017 | 38 | 0.040 |
Why?
|
| Transplantation, Isogeneic | 1 | 2017 | 68 | 0.040 |
Why?
|
| Apoptosis | 3 | 2016 | 7847 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2018 | 2851 | 0.040 |
Why?
|
| Cell Proliferation | 3 | 2016 | 7294 | 0.040 |
Why?
|
| RNA | 1 | 2022 | 1067 | 0.040 |
Why?
|
| Aminopterin | 1 | 2016 | 32 | 0.040 |
Why?
|
| Breast Neoplasms | 4 | 2018 | 16186 | 0.040 |
Why?
|
| Interleukin-12 | 1 | 2018 | 267 | 0.040 |
Why?
|
| Karyotype | 1 | 2017 | 237 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2018 | 586 | 0.040 |
Why?
|
| Infliximab | 2 | 2009 | 139 | 0.030 |
Why?
|
| Metapneumovirus | 1 | 2017 | 57 | 0.030 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2016 | 87 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2016 | 146 | 0.030 |
Why?
|
| DNA Methylation | 2 | 2016 | 2736 | 0.030 |
Why?
|
| Myeloma Proteins | 1 | 2015 | 27 | 0.030 |
Why?
|
| Premedication | 1 | 2016 | 133 | 0.030 |
Why?
|
| Interleukin-8 | 1 | 2018 | 531 | 0.030 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2016 | 128 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2016 | 157 | 0.030 |
Why?
|
| Medical Records | 1 | 2017 | 443 | 0.030 |
Why?
|
| Histone Code | 1 | 2016 | 86 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2018 | 827 | 0.030 |
Why?
|
| Histocompatibility Antigens | 1 | 2015 | 79 | 0.030 |
Why?
|
| Antigen-Presenting Cells | 1 | 2016 | 289 | 0.030 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2005 | 195 | 0.030 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2017 | 371 | 0.030 |
Why?
|
| Education | 1 | 2005 | 124 | 0.030 |
Why?
|
| Cell Separation | 1 | 2017 | 616 | 0.030 |
Why?
|
| Fucosyltransferases | 1 | 2015 | 78 | 0.030 |
Why?
|
| E-Selectin | 1 | 2015 | 110 | 0.030 |
Why?
|
| P-Selectin | 1 | 2015 | 110 | 0.030 |
Why?
|
| Carboplatin | 1 | 2018 | 879 | 0.030 |
Why?
|
| Platelet Transfusion | 1 | 2015 | 167 | 0.030 |
Why?
|
| Epidemiological Monitoring | 1 | 2014 | 83 | 0.030 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2016 | 337 | 0.030 |
Why?
|
| Genetic Vectors | 1 | 2020 | 1884 | 0.030 |
Why?
|
| Factor Analysis, Statistical | 1 | 2015 | 353 | 0.030 |
Why?
|
| Plasmids | 1 | 2016 | 952 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 1820 | 0.030 |
Why?
|
| Cell Death | 1 | 2016 | 689 | 0.030 |
Why?
|
| Nausea | 1 | 2016 | 540 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2015 | 7783 | 0.030 |
Why?
|
| Israel | 1 | 2013 | 59 | 0.030 |
Why?
|
| Hypoxia | 1 | 2017 | 467 | 0.030 |
Why?
|
| Viral Load | 1 | 2016 | 482 | 0.030 |
Why?
|
| Reoperation | 1 | 2018 | 1389 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2014 | 92 | 0.030 |
Why?
|
| Chile | 1 | 2013 | 68 | 0.030 |
Why?
|
| Testicular Neoplasms | 1 | 2018 | 554 | 0.030 |
Why?
|
| Living Donors | 1 | 2014 | 178 | 0.030 |
Why?
|
| Graft Rejection | 2 | 2009 | 865 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2005 | 480 | 0.030 |
Why?
|
| Protein Engineering | 1 | 2013 | 99 | 0.030 |
Why?
|
| Inflammation | 1 | 2023 | 2527 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2014 | 315 | 0.030 |
Why?
|
| Lymphatic Diseases | 1 | 2013 | 130 | 0.030 |
Why?
|
| Cytogenetics | 1 | 2013 | 152 | 0.030 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2014 | 175 | 0.030 |
Why?
|
| Transplantation | 1 | 2013 | 56 | 0.030 |
Why?
|
| India | 1 | 2013 | 314 | 0.030 |
Why?
|
| Antigens, Viral | 1 | 2015 | 520 | 0.030 |
Why?
|
| Transplantation Immunology | 1 | 2013 | 109 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2014 | 349 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2014 | 420 | 0.030 |
Why?
|
| Skin Diseases | 1 | 2016 | 368 | 0.030 |
Why?
|
| Gastroscopy | 1 | 2013 | 155 | 0.030 |
Why?
|
| Syndrome | 2 | 2008 | 1404 | 0.030 |
Why?
|
| Liver Diseases | 1 | 2017 | 605 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2014 | 551 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2013 | 485 | 0.030 |
Why?
|
| Lung | 1 | 2023 | 3267 | 0.020 |
Why?
|
| Thiotepa | 1 | 2012 | 132 | 0.020 |
Why?
|
| Tretinoin | 1 | 2014 | 621 | 0.020 |
Why?
|
| Primary Graft Dysfunction | 1 | 2012 | 35 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2017 | 2288 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2014 | 671 | 0.020 |
Why?
|
| Adenine | 1 | 2015 | 667 | 0.020 |
Why?
|
| Sex Factors | 1 | 2017 | 2192 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2017 | 2618 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 1212 | 0.020 |
Why?
|
| Mucositis | 1 | 2012 | 150 | 0.020 |
Why?
|
| Radioimmunotherapy | 1 | 2012 | 129 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2012 | 658 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2016 | 1053 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2016 | 1011 | 0.020 |
Why?
|
| Receptor Aggregation | 1 | 2010 | 15 | 0.020 |
Why?
|
| CD2 Antigens | 1 | 2010 | 29 | 0.020 |
Why?
|
| Serum Albumin | 1 | 2011 | 247 | 0.020 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2003 | 2412 | 0.020 |
Why?
|
| Immunological Synapses | 1 | 2010 | 31 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2010 | 5782 | 0.020 |
Why?
|
| Parathyroid Hormone | 1 | 2011 | 197 | 0.020 |
Why?
|
| Risk | 1 | 2015 | 1914 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2014 | 459 | 0.020 |
Why?
|
| Patient Safety | 1 | 2016 | 651 | 0.020 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 2010 | 73 | 0.020 |
Why?
|
| Perforin | 1 | 2010 | 52 | 0.020 |
Why?
|
| Yttrium Radioisotopes | 1 | 2012 | 210 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2012 | 322 | 0.020 |
Why?
|
| Lung Diseases | 1 | 2016 | 751 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2016 | 2465 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 6172 | 0.020 |
Why?
|
| Demography | 1 | 2011 | 435 | 0.020 |
Why?
|
| Palivizumab | 1 | 2010 | 65 | 0.020 |
Why?
|
| Animals | 4 | 2024 | 62771 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2010 | 596 | 0.020 |
Why?
|
| Topotecan | 1 | 2010 | 248 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2015 | 3648 | 0.020 |
Why?
|
| Piperidines | 1 | 2015 | 1089 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 1725 | 0.020 |
Why?
|
| Herpesvirus 4, Human | 1 | 2013 | 954 | 0.020 |
Why?
|
| Neutropenia | 1 | 2013 | 1001 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2016 | 1571 | 0.020 |
Why?
|
| Rabbits | 1 | 2010 | 1089 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2013 | 1620 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2016 | 2093 | 0.020 |
Why?
|
| Genetic Therapy | 1 | 2016 | 1732 | 0.020 |
Why?
|
| Bone Density | 1 | 2011 | 470 | 0.020 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2010 | 683 | 0.020 |
Why?
|
| Immunomodulation | 1 | 2009 | 253 | 0.020 |
Why?
|
| Prevalence | 1 | 2016 | 3420 | 0.020 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2007 | 147 | 0.020 |
Why?
|
| Whole Body Imaging | 1 | 2008 | 113 | 0.020 |
Why?
|
| Actins | 1 | 2010 | 616 | 0.020 |
Why?
|
| Disease Outbreaks | 1 | 2010 | 404 | 0.020 |
Why?
|
| Hospitals, University | 1 | 2008 | 219 | 0.020 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 3 | 1 | 2007 | 95 | 0.020 |
Why?
|
| Mice | 2 | 2024 | 35992 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2018 | 2984 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2016 | 1919 | 0.020 |
Why?
|
| Fatigue | 1 | 2013 | 1277 | 0.020 |
Why?
|
| Creatinine | 1 | 2009 | 545 | 0.020 |
Why?
|
| Logistic Models | 1 | 2014 | 3437 | 0.020 |
Why?
|
| Cancer Care Facilities | 1 | 2012 | 908 | 0.020 |
Why?
|
| Antigens, Differentiation | 1 | 2008 | 254 | 0.020 |
Why?
|
| Thiabendazole | 1 | 2006 | 11 | 0.020 |
Why?
|
| Ivermectin | 1 | 2006 | 18 | 0.020 |
Why?
|
| Atrial Fibrillation | 1 | 2014 | 749 | 0.020 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2016 | 1335 | 0.020 |
Why?
|
| Neoplasm Metastasis | 2 | 2009 | 5324 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2010 | 1855 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2014 | 1726 | 0.020 |
Why?
|
| Anthelmintics | 1 | 2006 | 70 | 0.020 |
Why?
|
| Hypereosinophilic Syndrome | 1 | 2006 | 86 | 0.020 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2010 | 631 | 0.020 |
Why?
|
| Liver | 2 | 2005 | 3126 | 0.020 |
Why?
|
| Gene Expression | 1 | 2013 | 3681 | 0.020 |
Why?
|
| Calcium | 1 | 2011 | 1598 | 0.020 |
Why?
|
| Mouth Mucosa | 1 | 2005 | 225 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 5438 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2016 | 3349 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 2008 | 580 | 0.010 |
Why?
|
| Anemia, Aplastic | 1 | 2005 | 233 | 0.010 |
Why?
|
| Eye | 1 | 2005 | 287 | 0.010 |
Why?
|
| Kidney Neoplasms | 1 | 2018 | 3142 | 0.010 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 1 | 2008 | 461 | 0.010 |
Why?
|
| Necrosis | 1 | 2005 | 603 | 0.010 |
Why?
|
| Hyperlipidemias | 1 | 2005 | 236 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2007 | 1436 | 0.010 |
Why?
|
| Anemia, Sickle Cell | 1 | 2005 | 371 | 0.010 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2009 | 1269 | 0.010 |
Why?
|
| Cyclosporine | 1 | 2002 | 295 | 0.010 |
Why?
|
| Survivors | 1 | 2007 | 1024 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2010 | 5837 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2009 | 4002 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 9078 | 0.010 |
Why?
|
| Mycoses | 1 | 2004 | 396 | 0.010 |
Why?
|
| Bacterial Infections | 1 | 2004 | 507 | 0.010 |
Why?
|
| Skin | 1 | 2005 | 1290 | 0.010 |
Why?
|
| Medical Oncology | 1 | 2009 | 1462 | 0.010 |
Why?
|
| Mutation | 1 | 2018 | 15854 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2006 | 4897 | 0.010 |
Why?
|
| Palliative Care | 1 | 2007 | 2154 | 0.010 |
Why?
|
| Quality of Life | 1 | 2003 | 4732 | 0.010 |
Why?
|